Skip to main content
logo
Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
11.55
+0.40 (3.59%)
Apr 14, 2026, 4:00 PM EDT - Market closed

Keros Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Cap
2283986421,2661,3231,403
Market Cap Growth
-48.91%-38.02%-49.29%-4.28%-5.71%-14.26%
Enterprise Value
-42.79124.9798.93948.291,0561,173
Last Close Price
11.5520.3615.8339.7648.0258.51
PE Ratio
5.028.85-3.17-7.65-11.57-23.22
PS Ratio
0.931.63180.848384.12-69.79
PB Ratio
0.741.311.123.814.775.77
P/TBV Ratio
1.422.541.043.524.375.61
P/FCF Ratio
2.153.76-3.94-9.97-18.55-22.21
P/OCF Ratio
2.123.70-3.99-10.17-18.88-22.57
EV/Sales Ratio
-0.5127.876280.09-58.36
EV/EBITDA Ratio
-1.81-0.47-5.61-9.26-20.95
EV/EBIT Ratio
-1.85-0.47-5.58-9.20-20.81
EV/FCF Ratio
-1.18-0.61-7.47-14.82-18.57
Debt / Equity Ratio
0.050.050.030.040.050.00
Debt / EBITDA Ratio
0.240.24-0.09-0.08-0.12-0.02
Debt / FCF Ratio
0.160.16-0.12-0.11-0.19-0.02
Net Debt / Equity Ratio
-0.89-0.89-0.95-0.95-0.96-0.94
Net Debt / EBITDA Ratio
-3.92-3.922.581.872.334.09
Net Debt / FCF Ratio
-2.55-2.553.322.493.733.62
Asset Turnover
0.510.510.010.0000.08
Quick Ratio
14.3614.3620.5013.5916.8620.94
Current Ratio
15.4515.4521.4514.2517.2721.23
Return on Equity (ROE)
19.90%19.90%-41.46%-50.19%-40.22%-23.27%
Return on Assets (ROA)
14.92%14.92%-42.70%-50.22%-40.85%-20.73%
Return on Invested Capital (ROIC)
225.61%225.61%-915.33%-1251.82%-887.57%-985.85%
Return on Capital Employed (ROCE)
14.92%14.92%-45.14%-53.45%-43.02%-22.30%
Earnings Yield
38.21%11.30%-31.59%-13.08%-8.64%-4.31%
FCF Yield
46.52%26.63%-25.36%-10.03%-5.39%-4.50%
Buyback Yield / Dilution
-1.13%-1.13%-27.14%-16.66%-8.17%-50.48%
Total Shareholder Return
-1.13%-1.13%-27.14%-16.66%-8.17%-50.48%
Updated Mar 4, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q